Silent Free Fall at Disease Onset: A Perspective on Therapeutics for Progressive Multiple Sclerosis
- 1University of Illinois at Chicago, United States
Central nervous system (CNS) degeneration occurs during multiple sclerosis (MS) following several years of reversible autoimmune demyelination and motor impairment. Progressive CNS degeneration appears later during the course of the disease, although it starts insidiously at the disease onset. Many different cell types are involved in the pathogenesis of MS. Furthermore, the response to the initial damage, which is specific for each individual, results in distinct pathogenetic pathways, and each MS patient presents unique therapeutic challenges. To effectively treat each MS patient, an identification of the various components of the disease should be done for each patient at the time of treatment. Until such individualized treatments become available, combined therapies directed at anti-inflammation, regeneration, and neuroprotection are the most effective treatments for this disease. This article focuses on targets and issues to be addressed at the disease onset for an effective treatment of progressive MS.
Keywords: Multiple scleorsis (MS), CNS degenerative disorders, Inflammation, Therapeutics, prevention
Received: 25 Jul 2018;
Accepted: 29 Oct 2018.
Edited by:Martin S. Weber, Universitätsmedizin Göttingen, Germany
Reviewed by:Moussa A. Chalah, Hôpitaux Universitaires Henri Mondor, France
Sonja Hochmeister, Medical University of Graz, Austria
Copyright: © 2018 LOPRESTI. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. PATRIZIA LOPRESTI, University of Illinois at Chicago, Chicago, United States, email@example.com